Compare CPSS & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPSS | IMUX |
|---|---|---|
| Founded | 1991 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.6M | 200.4M |
| IPO Year | 2010 | 2013 |
| Metric | CPSS | IMUX |
|---|---|---|
| Price | $8.91 | $15.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 25.2K | ★ 195.3K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1.27 | ★ 38.00 |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $434,470,000.00 | N/A |
| Revenue This Year | $147.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $40.08 | ★ N/A |
| Revenue Growth | ★ 10.41 | N/A |
| 52 Week Low | $6.67 | $0.51 |
| 52 Week High | $10.49 | $15.84 |
| Indicator | CPSS | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 42.03 | 61.45 |
| Support Level | $8.85 | $0.74 |
| Resistance Level | $9.40 | $15.81 |
| Average True Range (ATR) | 0.30 | 0.88 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 24.77 | 61.32 |
Consumer Portfolio Services Inc is a U.S based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.